Ryan L. Thompson of Watts Guerra LLP Moves to Consolidate Incretins Lawsuits in MDL No. 2452

Ryan L. Thompson, Partner, Watts Guerra LLP (Photo: Business Wire)

SAN ANTONIO--()--The 53 incretins pancreatic cancer lawsuits filed by Watts Guerra LLP, as well as about 100 other similar complaints filed nationwide, could be consolidated into Multi District Litigation (MDL) if the U. S. Judicial Panel on Multi District Litigation (JPML) grants the consolidation motion filed by Ryan L. Thompson.

The JPML panel, which consists of seven sitting federal judges, heard oral arguments from Thompson related to the consolidation motion filed on behalf of his firm’s clients, Moses Scott and Rosalie Duhon, on July 25, 2013 in Portland, Maine in In Re: Incretins Products Liability Litigation, MDL 2452.

Thompson, on behalf of Plaintiffs Scott and Duhon, argued that the Panel should consolidate the federal incretins litigation in the United States District Court for the Southern District of California under Judge Anthony J. Battaglia. Mr. Scott alleged in his original complaint that his late sister’s ingestion of various incretins medications caused her to develop pancreatic cancer and ultimately die. (See Moses Scott, Individually and as Estate Administrator of the Estate of Regina Kelly, Deceased v. Merck & Co., Inc., et. al., Case Number 3:12-cv-02549-AJB, In the United States District Court for the Southern District of California (2013)).

The cases involve a class of drugs known as the incretin mimetics, which includes Byetta, Januvia, Janumet, and Victoza, among others. This family of medications consists of two sub-groups, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. These drugs are prescribed for Type 2 diabetes and work by mimicking the incretin hormones the body normally produces to stimulate the release of insulin in response to a meal. They are used to lower blood sugar in Type 2 diabetics and to help prevent other diabetic complications.

The product liability and dangerous drug lawyers of Watts Guerra LLP filed the very first federal incretins injury and death lawsuits in the country last year. Since that time, other law firms have followed their lead and there are currently over 100 cases pending in federal courts across the country.

Mikal C. Watts and Ryan L. Thompson are proud to handle what is believed to be the largest incretin mimetics injury and wrongful death docket in the country. The dangerous drug lawyers of Watts Guerra LLP encourage victims to investigate their potential claims against the manufacturers of the various diabetes drugs, including Amylin Pharmaceuticals LLC, Eli Lilly & Company, Novo Nordisk, and Merck Sharp & Dohme Corp., by speaking to an experienced product liability lawyer quickly to make sure their claims are filed within applicable time limitations.

Watts Guerra LLP has handled hundreds of thousands of mass action claims across the country, and has won some of the most significant legal victories in American history. For more information about Watts Guerra LLP, please visit our Website, find us on Facebook, or follow us on Twitter.

Contacts

Watts Guerra LLP
Stacey Burke, 866-457-3403
National Marketing Attorney

Release Summary

The 53 incretins pancreatic cancer lawsuits filed by Watts Guerra LLP, as well as about 100 other similar complaints could be consolidated into Multi-District Litigation (MDL).

Contacts

Watts Guerra LLP
Stacey Burke, 866-457-3403
National Marketing Attorney